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A Mutation of COX6A1 Causes
a Recessive Axonal or Mixed Form
of Charcot-Marie-Tooth Disease
Gen Tamiya,1,* Satoshi Makino,1 Makiko Hayashi,2 Akiko Abe,2 Chikahiko Numakura,2 Masao Ueki,1
Atsushi Tanaka,3 Chizuru Ito,4 Kiyotaka Toshimori,4 Nobuhiro Ogawa,5 Tomoya Terashima,5
Hiroshi Maegawa,5 Daijiro Yanagisawa,6 Ikuo Tooyama,6 Masayoshi Tada,7 Osamu Onodera,7 and
Kiyoshi Hayasaka2,*
Charcot-Marie-Tooth disease (CMT) is the most common inherited neuropathy characterized by clinical and genetic heterogeneity.
Although more than 30 loci harboring CMT-causing mutations have been identified, many other genes still remain to be discovered
for many affected individuals. For two consanguineous families with CMT (axonal and mixed phenotypes), a parametric linkage anal-
ysis using genome-wide SNP chip identified a 4.3 Mb region on 12q24 showing a maximum multipoint LOD score of 4.23. Subse-
quent whole-genome sequencing study in one of the probands, followed by mutation screening in the two families, revealed a
disease-specific 5 bp deletion (c.24710_2476delCACTC) in a splicing element (pyrimidine tract) of intron 2 adjacent to the third
exon of cytochrome c oxidase subunit VIa polypeptide 1 (COX6A1), which is a component of mitochondrial respiratory complex IV
(cytochrome c oxidase [COX]), within the autozygous linkage region. Functional analysis showed that expression of COX6A1 in
peripheral white blood cells from the affected individuals and COX activity in their EB-virus-transformed lymphoblastoid cell lines
were significantly reduced. In addition, Cox6a1-null mice showed significantly reduced COX activity and neurogenic muscular atro-
phy leading to a difficulty in walking. Those data indicated that COX6A1 mutation causes the autosomal-recessive axonal or
mixed CMT.Charcot-Marie-Tooth disease (CMT) is the most common
inherited neuromuscular disease characterized by clinical
and genetic heterogeneity, which has been traditionally
subdivided into two major subgroups, demyelinating and
axonal forms. Initially, genes encoding major myelin pro-
teins including peripheral myelin protein 22 (PMP22 [MIM
601097])1 and myelin protein zero (MPZ [MIM 159440])2
were identified as genes involved in demyelinating CMT
as well as mitofusin 2 (MFN2 [MIM 608507])3 in axonal
CMT. So far, mutations causing CMT have been identified
inmore than 30 loci. To identify the genetic background of
Japanese CMT, we analyzed the disease-causing mutation
in about 350 affected individuals; however, we could not
identify the causative mutations in about 50% of demye-
linating CMT and 80% of axonal CMT.
We studied two families with affected members from
consanguineous marriages at different sites in Japan
(Figure 1A). The affected siblings of family 1 initially had
slightly reduced median motor nerve conduction veloc-
ities (NCVs) and onion bulb formation in the sural nerve
at young ages, but they had motor NCVs below 38 m/s
when they were aged 30–39 years, indicating mixed CMT
(Tables S1 and S2 available online). The affected member
of family 2 had slightly reduced median motor NCVs at
age 39, indicating axonal phenotype (Tables S3 and S4).
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294 The American Journal of Human Genetics 95, 294–300, Septembnections each other, their affected members share similar
disease phenotypes and a deduced mode of inheritance
(i.e., recessive). Informed consent was obtained from all
subjects, and all procedures were approved by the Research
Ethics Committees of Yamagata University Faculty of
Medicine and Niigata University School of Medicine. For
these families, family 1 with two affected members from
the marriage between second cousins and family 2
with one from that between first cousins once removed
(Figure 1A), we carried out a parametric linkage study
using genome-wide 6.5K SNP chip. A genome-wide SNP
genotyping was performed for ten members from the
two families with the HumanLinkage V Panel (Illumina).
A multipoint linkage analysis was performed with Allegro
v.2 and a human genetic map based on NCBI dbSNP Build
123 and identified a significant linkage in a 4.3 Mb region
on 12q24 covered by nine SNPs showing multipoint
LOD scores of 3.85–4.23 at q ¼ 0.00 (Figures 1B, 1C, and
S1; Table 1).
Subsequent whole-genome sequencing for the proband
from family 1 was performed on a Genome Analyzer IIx
system (Illumina), followed by annotation, filtering, and
assessing potential effects of variants (Tables S5 and S6).
It yielded enough data (a mean depth of 49.63) to
detect sequence variants by comparison with a reference
sequence (Table S5). Of a total of 3,716,455 variantsamagata University, Yamagata 990-9585, Japan; 2Department of Pediatrics,
ch Institute of Medical Sciences, Faculty of Medicine, Yamagata University,
e, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan;
, Japan; 6Molecular Neuroscience Research Center, Shiga University of Med-
rain Research Institute, Niigata University, Niigata 951-8585, Japan
-u.ac.jp (K.H.)
y of Human Genetics. All rights reserved.
er 4, 2014
0 50 100 150
Chromosome 12
Position (cM)
LO
D
 S
co
re
−9
−6
−3
0
3
6
COX6A1
KSR2
PEBP1
119M 120M 121M 122M
TAOK3WSB2
HSPB8
CCDC60
TMEM233
GATCDYNLL1
POP5
CABP1
SPPL3
MELC
ANAPC5
RNF34
12q24.22 - q24.31
118M
rs885487
rs1530541
rs1064951rs610694rs4590911
rs1520780 rs2730753
rs1016203 rs477467 rs2422
3 noxe2 noxe1 noxe
COX6A1
2 ylimaF
120,876K 120,877K 120,878K
WT
...ttatctaactgacatctt -----cacagCCGT...
A
C
D
E
B
Chromo ome 12
50 100 150 (cM)
Family 1 Family 2
Autozygous region
FBXO21
rs1179992
P2RX7
C12orf43
GA C A T C T TT TAC C C GC A
CA C A T C T TT TAC C C GC T
CA C A T C T TT TAC C C GC T
CA C A T C T TT TAC C C GC T
5-bp deletion
(c.247-10_247-6del)
LO
D
 s
co
re
V-1 (affected)
IV-1
IV-2
V-2
(+/+)
(+/-)
(+/-)
(+/-)
Branch site
...ttatctaactgacatctt cactccacagCCGT...
Splicing acceptor
mutant type
wild-type
PP
I
II
III
IV
V
I
II
III
IV
V
1 2
1 2 3 4
1 2
1 2
3
䠉2
Figure 1. Genomic Analyses in the CMT
Families
(A) Pedigrees of two consanguineous CMT
families, from which a total of ten mem-
bers in broken line boxes were sampled.
(B)Multipoint LOD scores on chromosome
12 using these ten members from two fam-
ilies with the HumanLinkage V SNP chip.
We extracted genomic DNA from periph-
eral blood using the QIAamp DNA spin
columns (QIAGEN) and quantified them
using the Quant-iT PicoGreen dsDNA
Assay Kit (Life Technologies). Genotyping
was performedwith the GoldenGate Geno-
typing Universal-32 kit on a BeadArray
Reader System (Illumina) according to the
manufacturer’s assay guide. Genotype calls
were made using the Genotyping module
of the GenomeStudio v2009.1 software
(Illumina). A multipoint linkage analysis
was performed with Allegro v.24 and a
human genetic map based on NCBI dbSNP
Build 123 (see also Figure S1).
(C) Gene map in the significant linkage re-
gion on 12q24. These physical coordinates
are taken from UCSC Genome Browser
build hg19, RefSeq, and dbSNP 138
(UCSC Genome Browser database: 2014
update).
(D) A disease-specific 5 bp deletion
(c.24710_2476delCACTC) in the py-
rimidine tract near to the splicing acceptor
near to the third exon of COX6A1.
(E) Validation and distribution of the 5 bp
deletion among the CMT family members
by Sanger-based PCR direct sequencing
(see also Table S10).(Table S7), after filtering out known or heterozygous vari-
ants, six were suspected to be deleterious by a majority
rule approach using five prediction methods: PolyPhen-2,
Grantham, PROVEAN, SIFT, and Mutation Taster (Table
2; see also Table S8 for a relaxed rule). Among them, only
a 5 bp deletion (c.24710_2476delCACTC; RefSeq acces-
sion number NM_004373.3) was located just in a long run
of homozygosity spanning 3.7 Mb, between rs10774925
and rs503720, in the significant linkage region on 12q24
(Figures 1C and 1D; Tables 1 and S9; see also Figure S2
and Table S10). In the two families, the 5 bp deletion was
cosegregated perfectly with the disease state (Figures 1E
and S3). Mutation screening by PCR assay detected the
5 bp deletion in none of 1,452 control chromosomes
from diverse ethnic groups (Table S11).The American Journal of Human GenAs expected from the fact that this
disease-specific 5 bp deletion disrup-
ted an intronic splicing element (py-
rimidine tract11–13) adjacent to the
boundary of the second intron and
the third exonof cytochrome coxidase
subunit VIa polypeptide 1 (COX6A1
[MIM 602072]) whose expression is
almost ubiquitous excepting skeletal
muscles (see Su et al.10 for humanand Figure S4 for mouse), quantitative RT-PCR assay de-
tected the significantly reduced (<1/5 of controls; p <
0.001) expression of the normally spliced form of
COX6A1 in peripheral white blood cells from two affected
members of family 1 (Figure 2A, see also Table S12). Consis-
tent with these findings, their cultured cell lines showed
statistically significant reductions in the COX6A1 expres-
sion (p < 0.001; Figure 2B, see also Table S12), cytochrome
c oxidase (COX) activity (Figure 2C), and total ATP contents
(Figure 2D) in these affected individuals relative to controls.
Detaileddescriptions are found in the legends of figures and
tables for all experiments including expression analysis of
COX6A1mRNA (see also Figure S5 and Table S12), determi-
nation of COX activity, and ATP amount. We performed
two additional experiments: (1) the qRT-PCR using threeetics 95, 294–300, September 4, 2014 295
Table 1. Multipoint LOD Scores on 12q24 and Estimated Haplotypes in the Significant Linkage Region
Markers Positionsa
LOD
Score
Family 1 Family 2
IV-1
(Father)
IV-2
(Mother)
V-1
(Affected)
V-2
(Affected)
V-3
(Brother)
V-4
(Brother)
IV-1
(Father)
IV-2
(Mother)
V-1
(Affected)
V-2
(Brother)
rs885487 117539934 infinity 2 1 2 1 2 1 2 2 2 1 1 1 2* 2 2* 2 2* 2* 2* 2
rs1530541 118229731 4.0597 2* 2 2* 2 2* 2* 2* 2* 2* 2 2* 2 2* 1 2* 2 2* 2* 2* 1
rs4590911 118562757 4.2433 1* 2 1* 2 1* 1* 1* 1* 1* 2 1* 2 2* 2 2* 2 2* 2* 2* 2
rs1520780 119039725 4.2338 2* 1 2* 2 2* 2* 2* 2* 2* 1 2* 1 2* 2 2* 2 2* 2* 2* 2
rs2730753 119171974 4.2317 2* 1 2* 2 2* 2* 2* 2* 2* 1 2* 1 2* 2 2* 1 2* 2* 2* 2
rs1016203 119423542 4.2249 2* 2 2* 2 2* 2* 2* 2* 2* 2 2* 2 2* 2 2* 1 2* 2* 2* 2
rs477467 119927992 4.1386 2* 2 2* 1 2* 2* 2* 2* 2* 2 2* 2 2* 2 2* 2 2* 2* 2* 2
rs2422 120565188 4.0416 1* 2 1* 1 1* 1* 1* 1* 1* 2 1* 2 2* 2 2* 2 2* 2* 2* 2
5 bp del 120878247 þ*  þ*  þ* þ* þ* þ* þ*  þ*  þ*  þ*  þ* þ* þ* 
rs610694 121304826 3.8859 2* 2 2* 2 2* 2* 2* 2* 2* 2 2* 2 1* 1 1* 2 1* 1* 1* 1
rs1179992 121495432 3.8466 1* 2 1* 2 1* 1* 1* 1* 2* 2 1* 2 2* 2 2* 1 2* 2* 2* 2
rs1064951 121878659 1.7247 1 2 2 2 1 2 1 2 2 2 2 2 2* 2 2* 2 2* 2* 2* 2
Haplotypes were reconstructed using Allegro v.2 with ‘‘HAPLOTYPE’’ option from each family data including 5 bp deletion (c.24710_2476delCACTC). Asterisk
indicates the putative disease-associated haplotypes in each family.
aPhysical coordinate is taken from dbSNP 138 (UCSC Genome Browser, 2014 update).primers specific to the mutant transcript showed its low
level (Figure S6 and Table S12); and (2) the immunoblot
showed no band at around 11.0 kDa for the mutant pro-
tein (Figure S7). These results suggest that the deletion
leads to alternative splicing events triggering a potential
nonsense-mediated RNA decay.
Finally, we examined commercially provided Cox6a1-
null mice (Figure S8 and Table S13). All experimental pro-
cedures were performed according to the animal welfare
regulations of Yamagata University Faculty of Medicine
and Shiga University of Medical Science, and the study
protocol was approved by the Animal Subjects Committee
of Yamagata University Faculty of Medicine and Shiga Uni-Table 2. List of Homozygous and Potentially Deleterious Variants Nom
Chr Start
Alleles
Gene (MIM ID) TypesRef Variant
12 120878247 CACTC – COX6A1 splicing
2 114257705 C – FOXD4L1
(MIM 611084)
frame-shift
14 24470691 – A DHRS4L2
(MIM 615196)
frame-shift
19 20807178 – A ZNF626 (NA) frame-shift
2 114257443 A C FOXD4L1
(MIM 611084)
nonsynonymou
8 126443464 G T TRIB1
(MIM 609461)
nonsynonymou
To assess potential variant effects for nonsynonymous variants, we used PolyPhen-2
v.137 (score > 151), PROVEAN v.1.1.3 (score < 2.5),6 SIFT (score < 0.05),7 and
terious variants voted by at least two prediction methods. Furthermore, we also r
gcrma data set)9,10 (see also Table S8).
296 The American Journal of Human Genetics 95, 294–300, Septembversity of Medical Science. The null mice showed lack of
COX6A1 products (Figure 3A) and remarkable behavioral
phenotypes including difficulty in walking (Figure 3B;
Movie S1). Histological examinations revealed that the
null mice had thinned sciatic nerves (Figure 3C) and
neurogenic muscular changes including small angular
fiber and small group atrophy (Figure 3D), although no
remarkable neurodegeneration was found. In addition,
consistent with the findings in the affected individuals,
the null mice showed statistically significant reductions
in COX activity and ATP contents in liver cells (p <
0.001; Figures 4A and 4B) and delayed motor NCV (p <
0.01; Figure 4C) relative to control animals.inated by at Least Three of Five Prediction Methods
Accession
Changes
Nucleotide Protein
NM_004373.3 c.24710_2476delCACTC NA
NM_012184.4 c.876del p.Gly293Alafs*151
NM_001193637.1 c.204_205insA p.His69Thrfs*69
NM_001076675.2 c.1505dup p.Ile503Hisfs*95
s NM_012184.4 c.610A>C p.Lys204Gln
s NM_025195.3 c.320G>T p.Arg107Leu
v.2.2.2 (HumVar; score> 0.85),5 Grantham Score from SeattleSeq Annotation
Mutation Taster (predicted as ‘‘disease causing’’)8 and listed potentially dele-
eferred gene expression in human whole brain on BioGPS (GeneAtlas U133A,
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Figure 2. COX6A1 Expression and COX
Activity Levels
(A and B) COX6A1 expression in fresh
whole-blood from a control and the two
affected individuals from family 1 (A) and
in EBV-transformed B cell lines from four
controls and the two affected individuals
(B). Lymphoblastoid cells from two
affected members in the family 1 were
immortalized by infection with the Ep-
stein-Barr virus (VR-1492; American Type
Culture Collection). Immortalized cells
from the four healthy Japanese individuals
(HEV0031, HEV0032, HEV0038, and
HEV0041) were provided by RIKEN Bio-
Resource Center. Total RNA was extracted
using QIAamp RNA Blood Mini Kit or
AllPrep DNA/RNA Kit (QIAGEN) according
to the manufacturer’s instructions with
on-column DNase I treatment. After deter-
mining RNA concentrations using Quant-
iT RiboGreen RNA Assay Kit (Life
Technologies), 400 ng of total RNA per
40 ml reaction was used to synthesize
cDNA using the High-Capacity cDNA
Reverse Transcription Kit (Life Technolo-
gies) with random primers. Absolute
quantification for COX6A1 was performed
using a custom TaqMan assay (Table S12).
PCR products were ligated into pGEM-T
easy vector (Promega) and isolated plasmid DNA was then linearized by EcoRI digestion. Before use, plasmid concentration was deter-
mined by Quant-iT PicoGreen dsDNA Assay Kit and serial dilutions were performed to generate standard curve. Real-time PCR was
conducted using TaqMan Universal Master Mix II (Life Technologies) with a 7500 Fast real-time PCR system (Life Technologies). Each
reaction was run in triplicate and contained 2 ml of cDNA template in a final reaction volume of 20 ml and data were analyzed with
7500 Software v.2.0.2.
(C andD) COX activity (C) and ATP amount (D) inmitochondrial fractions from the same four controls and two affected individuals’ cell
lines. For the determination of COX activity, we used a Cytochrome c Oxidase Assay kit (Sigma-Aldrich). Mitochondrial fractions were
obtained from cells by homogenization in homogenization buffer (20 mM HEPES-KOH [pH 7.4], 220 mM mannitol, 70 mM sucrose,
1 mM EDTA, 13 protease inhibitor). The determination of COX activity was based on a colorimetric assay that quantifies the oxidation
of ferrocytochrome c to ferricytochrome c via cytochrome c oxidase, a reaction that results in a decrease in absorbance at 550 nm. After
measurement of absorbance, COX activity was calculated according to manufacturer’s instructions. The amount of ATP was measured
using a Lumino assay detecting cellular-ATP kit (CA100; Wako Pure Chemical Industries). The collected cells (1,000 cells per well) were
used according to manufacturer’s instructions. All experiments were triplicated per sample and tested using t test for the difference be-
tween controls mean and each affected individual mean. ***p < 0.001. The error bars represent the standard deviation.Haplotype estimation around the linkage region reveals
that the 5 bp deletion is harbored in background haplo-
types that differ between family 1 and 2 (Tables 1 and
S14; Figures S9 and S10), suggesting that this mutation
occurred independently on each the haplotype origin.
The two independent mutations in human CMT families
and the null allele in mice consistently indicate that the
5 bp deletion can cause the disease phenotype through
deficiency of COX6A1 leading to the reduced COX activity
in affected individuals’ peripheral nerves as well. The
COX6A1 is expressed in the sciatic nerve as well as other
tissues including lung, kidney, liver, and brain. Despite
its expression in multiple tissues, the affected individuals
carrying COX6A1 mutation show no signs and symptoms
other than that of the peripheral nervous system. It is
interesting to note that the surfeit 1 (SURF1 [MIM
185620]) encodes one of assembly factors of COX whose
mutations cause demyelinating CMT accompanying with
axonal loss14 leading to multisystem involvement with
nystagmus, hearing loss, kyphoscoliosis, and brain MRIThe Americanabnormalities. In contrast, COX6A1 is small polypeptide
required for the stability of holoenzyme. It is likely that
the focal symptoms of our affected individuals are due to
such narrow function, hypomorphic nature of the mutant
allele, and/or the possibility for the residual amount of
COX6A1 to warrant sufficient COX activity in other tissues
as to maintain bioenergetic compensation. As another pos-
sibility, COX6A1 deficiency might be compensated by
heart/muscle isoform, cytochrome c oxidase subunit VIa
polypeptide 2 (COX6A2) in the other tissues or interfere
with forming a stable COX assembly especially in the
mitochondria of peripheral nervous system. Such mito-
chondrial respiratory chain deficiency might increase
the vulnerability of nerve cells.15–18 Finally, the tissue spec-
ificity might reflect the differential vulnerability to
COX6A1 deficiency among them, as shown in many
known examples such as TAF1 RNA polymerase II, TATA
box binding protein (TBP)-associated factor, 250 kDa
(TAF1),19 huntintin (HTT),20 and superoxide dismutase 1,
soluble (SOD1).21 However, a molecular mechanismJournal of Human Genetics 95, 294–300, September 4, 2014 297
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Figure 3. Characterization of Cox6a1
Knockout Mice
(A) Immunoblot of COX6A1 and voltage-
dependent anion channel (VDAC) as con-
trol in a wild-type and Cox6a1 knockout
null mice. Mice aged 7–8 weeks, three
(one male and two female) knockout and
three (two male and one female) wild-
type were anesthetized and perfused with
10 mM PBS. Mitochondria fractions were
obtained from liver tissue and applied to
immunoblot. 20 mg of protein was loaded
into a SDS-PAGE and transferred to the
polyvinylidene difluoride membrane. The
primary antibody for COX6A1 (mouse
monoclonal, ab110265; abcam) is diluted
1:1,000 and secondary antibody for anti-
COX6A1 (anti-mouse IgG, HRP-conju-
gated, 315-035-003; Jackson ImmunoRe-
search) is diluted 1:10,000. All blotting is
carried out in 5% skim-milk/TBS solutions
at room temperature for 1 hr.
(B) Motor coordination and balance was
assessed as the latency to fall in the rota-
rod. Mice aged 7–8 weeks, four (two male
and two female) knockout and four (two
male and two female) wild-type were
used. Each mouse underwent the same
4 day procedure on a rota-rod (MK-660A;
Muromachi Kikai). The first 3 days were
used to train the mice (four sessions of
60 s each, walking at 20 rpm). The test ses-
sions were run on the last day. The mice
performed two series of three trials (10,
15, and 20 rpm) at each speed, with a
10 min rest period between trials. The
latency to fall was recorded with a cut-off
at 120 s. The difference between the wild-
type and knockout null mice means were
tested using t test. ***p < 0.001. The error
bars represent the standard deviation.
(C and D) Histological examinations by
toluidine blue staining sections of mice
sciatic nerves at lower magnification (C)
and hematoxylin-eosin staining sections
of mice lower limb muscles (D). Arrow in-
dicates a smaller number of fibers are
involved in small group atrophy and
arrowhead indicates small angular fibers
despite the limited numbers. Mice aged
7–8 weeks, four (two male and two female) knockout and four (two male and two female) wild-type were anesthetized and perfused
with 10mMPBS, followed by a fixative of 4% paraformaldehyde (for legmuscle) or 2.5% glutaraldehyde (for sciatic nerve) in 0.1M phos-
phate buffer. Sciatic nerve specimens were fixed in 2.5% glutaraldehyde in phosphate buffer for 2 hr at room temperature. After post-
fixation with 1% OsO4, the tissues were embedded in epoxy resin. Tissue blocks were sectioned at 1 mm thickness and stained with
toluidine blue for light microscopic examination. For the histological analysis of leg muscle, mice tissues were postfixed in 4%
paraformaldehyde for 48 hr at 4C. The muscle tissues were dissected out and then incubated overnight in 10% sucrose in phosphate
buffer. After snap freezing with CO2 gas, tissue blocks were sectioned at 20 mm thickness in a cryostat and stained with hematoxylin and
eosin.between potential dysfunctions of the respiratory chain
and the disease phenotype is still unclear. Our findings
warrant further mechanistic analysis of structural analysis
of COX holoenzyme, COX activity, and assembly in
different tissues, including brain, heart, and, as a ‘‘positive
control,’’ skeletal muscle. To disentangle their high-order
functional interplay, the results from our genetic study
would warrant further mechanistic analyses of the mito-
chondrial involvements in the peripheral nervous system.298 The American Journal of Human Genetics 95, 294–300, SeptembOn the other hand, the multiple mutation events resulting
in the same deletion in the pyrimidine tract imply that
this site may be a mutational hotspot in human, so that
there is a possibility that this deletion would be found
across the world, especially from families with consanguin-
eous loop, under the same scenario as Charcot-Marie-
Tooth disease type 2F (CMT2F [MIM 606595])22 or he-
reditary motor and sensory neuropathy, proximal type
(HMSN-P [MIM 604484]).23,24er 4, 2014
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Figure 4. COX Activity and Electrophysiological Analysis in Mice
(A and B) COX activity in mitochondrial fractions from livers (A)
and ATP amount in liver homogenates (B) from three wild-type
and knockout null mice, respectively. Experiments for COX activ-
ity and ATP amount were triplicated per sample and all experi-
ments were tested using t test for the difference between the
wild-type and knockout mice means.
(C) Nerve conduction velocity of sciatic nerve from mice.
Studies were demonstrated at 7–10 weeks of age, six (three
male and three female) wild-type and seven (five male and
two female) null mice with Sapphire (Medelec) under anes-
thesia of pentobarbital sodium (5 mg/kg i.p.). At the right dor-
sal femoral, sciatic nerve was exposed by opening up overlying
skin and electrically stimulated using needle electrodes at
the sciatic notch and at the knee joint level under 37C 5
0.5C. The compound muscle action potential (CMAP) evoked
by the two parts of stimuli were recorded at gastrocnemius.
Motor nerve conduction velocity (NCV) was calculated
with dividing the distance between the sciatic notch and
knee joint level by the delta latency between the two CMAP
curves. Asterisks indicate the level of statistical significance
(**p < 0.01; ***p < 0.001). The error bars represent the stan-
dard deviation.Supplemental Data
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